Houston organization doles out over $775,000 in prizes to women-led health tech startups

and the winner is

Mara McFadden (left), CEO of Endolumik, took home the top prize at the Ignite Fire Pitch Competition. Photo courtesy of Ignite

After virtual and postponed events, Ignite Healthcare Network finally got to honor its 2021 cohort and name the annual winners.

The Fifth Annual Fire Pitch Competition was slated to take place last November, but was postponed to January. Affected by the Delta and then Omicron variants of COVID-19, the event finally got to return to in-person networking and pitches on Thursday, March 3.

"The opportunity to bring people together is a really different level of engagement and energy," Ayse McCracken, founder and board chair of Ignite, says ahead of the awards event. "We love seeing the energy that's being generated in Houston around innovation — and particularly health care innovation."

Seven companies pitched and three were awarded monetary prizes. Morgantown, West Virginia-based Endolumik, which has developed a patent-pending fluorescence-guided device to improve visualization and safety of robotic and laparoscopic bariatric operations, took home the top prize, which included a total of $500,000 in investment prizes from the Texas Medical Center Venture Fund and Wavemaker Three-Sixty Health.

Second place was awarded to Rx Bandz of Locust Valley, New York. The company created the MiniJect, the world’s smallest military-grade auto-injector designed to deliver a wide range of injectable medication, and was awarded $250,000 from the Texas Halo Fund and $25,000 from The Southwest National Pediatric Device Innovation Consortium.

San Antonio-based Hera Biotech took third place and was awarded a pilot program prize with Banner Health. Hera has developed the first non-surgical, tissue-based test capable of diagnosing endometriosis.

Ignite taps into Houston health care institutions to provide opportunities for its cohort of companies. According to a news release, this year’s partner organizations included Houston Methodist, Memorial Hermann Health System, Texas Children’s Hospital, Texas Children’s Pediatrics, The Menninger Clinic, Banner Health, Kindred Healthcare, Aetna, Commonwealth Care Alliance, BLUE KC, Hospital for Special Surgery, Summit Health, TMC Ventures, Texas Heart Institute, Golden Seeds, Portfolia, The Artemis Fund, Wavemaker 360 Health, Prosalus Capital Partners, 7Wire Ventures, Texas Halo Fund, Unity Point Ventures and others.

The judges who evaluated the competition’s panel of companies included:

  • Jay Goss, MBA General Partner, Wavemaker Three-Sixty Health
  • Amanda Hammel, Chief Information Officer, Memorial Hermann Health System
  • Karen Hill, MD, MBA, SVP and Chief Medical Officer, Texas Children’s Health Plan
  • Tom Luby, PhD, Director, Texas Medical Center Innovation Institute
  • Fiona Mack, PhD, Head of JLABS @TMC
  • Roberta Schwartz, PhD, EVP and Chief Innovation Officer, Houston Methodist Hospital
  • Andrew Truscott, Global Health Technology Lead, Accenture
Ria Health took home first place at the third annual Fire Pitch Competition. Courtesy of Ignite Healthcare

Female founders win big at this Houston health tech pitch competition

pitch perfect

All it takes is a spark for something to ignite, and, at the third annual Fire Pitch Competition by the Ignite Healthcare Network, eight female founders set the stage on fire.

The Fire Pitch Competition first started in 2017 to shine a spotlight on female entrepreneurs in health care. With two successful events under her belt, Ayse McCracken says she knew she could do more to help these women with their business ideas.

"What we discovered is that it's not enough. Startups get to pitch all over, and they want to invest their time wisely," McCracken says. "And it's not enough for the rest of the ecosystem — the customers — and the investors want companies that actually are investable."

So, this summer, McCracken and her team launched a mini accelerator. Thirteen companies participated in the Fire Pitch Customer-Partner Program that matched the companies with potential customers, pilot opportunities, and more. Participating customer organizations have included Humana, Houston Methodist, Memorial Hermann Health System, Gallagher, Texas Children's Hospital, Texas Children's Pediatrics, DePelchin, Next Level Urgent Care, University of Houston College of Medicine, VillageMD, and The Menninger Clinic.

Then, eight finalists of the group were selected to go on to pitch at the Fire Pitch.

Also new this year: More cash prizes. In previous years, the Fire Pitch has around $20,000 on the table. This year's awards doled out $265,000 in cash and investment prizes to six of the eight companies that pitched. The panel of five judges included: Babs Carryer, entrepreneur, and director of Big Idea Center for the University of Pittsburgh's Innovation Institute; Tom Luby, director of the Texas Medical Center Innovation Institute; Kerry Rupp, partner at True Wealth Ventures; Sarah Sossong, principal at Flare Capital Partners; and Andrew Truscott, managing director for Health and Public Service at Accenture.

Here's which companies took home prizes at the 2019 Fire Pitch Competition at the Texas Medical Center's Innovation Institute on October 17.

First place: Ria Health

Ria Health, a San Francisco-based elemental health practice that uses technology and care to provide treatment for Alcohol Use Disorder, was the big winner at the pitch event.

Jen Douglas, CFO of the company, took home first place and the $15,000 prize from Ignite Healthcare Network, but the company also snagged one of the new awards this year. The Texas Medical Center's Innovation Institute awarded Ria Health with a $50,000 investment prize. Ria Health previously participated in the TMCx08 digital health cohort, so the team is very familiar with Houston and the TMC.

Second place: SoundScouts

Sydney, Australia-based SoundScouts is on a mission to help early detection of hearing in school aged children. Carolyn Mee, founder and CEO, represented the company on the stage. She took home second place, which didn't come with an investment or cash prize.

Third place: Savonix

Savonix also didn't walk away with any money, but was recognized by the judges for founder and CEO Mylea Charvet's pitch. The San Francisco-based company is a digital cognitive assessment platform that can easily and cheaply gauge cognitive function.

Texas Halo Fund $100,000 award: PATH EX

The biggest winner of the night based on investment size was Houston-based PATH EX. Led by CEO and co-founder, Sinead Miller, PATH EX has a solution to hospitals' biggest killers: Sepsis. The current TMCx company has a unique pathogen extraction platform that can directly capture and eradicate bacteria.

Miller accepted a new award for this year's program that came with a $100,000 investment from the Texas Halo Fund.

Texas Halo Fund $50,000 award: PyrAmes 

One award wasn't enough for the Texas Halo Fund, which handed out a second new award to Cupertino, California-based PyrAmes. Presented by co-founder and CTO, Xina Quan, the company has created a wearable blood pressure monitor that is reliable and nonintrusive to patients. Quan accepted the $50,000 investment from the fund.

Houston Angel Network $50,000 award: Materna Medical 

San Francisco-base Materna Medical, which created a device to help protect and prepare expecting mothers' pelvic health ahead of childbirth, took home the last investment prize. President and CEO Tracy MacNeal presented the company and accepted the Houston Angel Network's $50,000 award.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings